Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects

The pharmacokinetics of a single i.v. dose of the new racemic beta-adrenoceptor-blocker nebivolol [0.073 mg base.kg-1 ideal body weight (IBW)] was studied in 9 obese (157% IBW) and 9 non-obese healthy volunteers (98% IBW). Each group contained 4 men and 5 women, aged 32 years, including one poor hyd...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 1997, Vol.51 (6), p.493-498
Hauptverfasser:	CHEYMOL, G, WOESTENBORGHS, R, SNOECK, E, IANUCCI, R, LE MOING, J.-P, NADITCH, L, LEVRON, J. C, POIRIER, J. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - pharmacokinetics Adrenergic beta-Antagonists - pharmacology Adult Antihypertensive agents Benzopyrans - pharmacokinetics Benzopyrans - pharmacology Biological and medical sciences Blood Pressure - drug effects Cardiac Output - drug effects Cardiovascular system Chromatography, High Pressure Liquid Ethanolamines - pharmacokinetics Ethanolamines - pharmacology Female Half-Life Heart Rate - drug effects Humans Lipids - blood Male Medical sciences Nebivolol Obesity - metabolism Obesity - physiopathology Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!